U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2CO3.2La.2HO.H2O
Molecular Weight 449.8587
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Lanthanum carbonate hydroxide hemihydrate

SMILES

O.[OH-].[OH-].[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O

InChI

InChIKey=CUEBJKMXYWSUDB-UHFFFAOYSA-H
InChI=1S/2CH2O3.2La.3H2O/c2*2-1(3)4;;;;;/h2*(H2,2,3,4);;;3*1H2/q;;2*+3;;;/p-6

HIDE SMILES / InChI

Molecular Formula La
Molecular Weight 138.90547
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CHO3
Molecular Weight 61.0168
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Lanthanum hydroxide (La(OH)3) is a rare novel earth compound which has so far been fabricated with various morphologies such as nanopowders, nanotubes, nanowires, nanorods and nanobelts from different methods like solvothermal, hydrothermal, sol-gel and template assisted routes. This compound has many attractive applications in gas-exhaust convectors, optical coatings, catalysts, superconductors, hydrogen storage materials and next generation of high dielectric constant gate dielectrics. It is a useful carrier precipitate for a number of ions. It was applied to the collection of traces of aluminum, bismuth, gold, iridium, iron, lead, thallium and titanium in silver metal. It is a predecessor Lanthanum oxide, which has a great interest as catalyst material.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
FOSRENOL

Approved Use

FOSRENOL is a phosphate binder indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).

Launch Date

2004
PubMed

PubMed

TitleDatePubMed
A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.
2009-10
Patents
Substance Class Chemical
Created
by admin
on Wed Apr 02 20:52:47 GMT 2025
Edited
by admin
on Wed Apr 02 20:52:47 GMT 2025
Record UNII
GJ3YBS3GN9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Lanthanum, [carbonato(2-)-O]hydroxy-, hydrate (2:1)
Preferred Name English
Lanthanum carbonate hydroxide hemihydrate
Systematic Name English
Code System Code Type Description
FDA UNII
GJ3YBS3GN9
Created by admin on Wed Apr 02 20:52:47 GMT 2025 , Edited by admin on Wed Apr 02 20:52:47 GMT 2025
PRIMARY
CAS
113030-84-5
Created by admin on Wed Apr 02 20:52:47 GMT 2025 , Edited by admin on Wed Apr 02 20:52:47 GMT 2025
PRIMARY